Centogene and Lifera's new joint venture - Lifera Omics; increase access to world-class multiomic testing in the Kingdom

Lifera Omics is a new joint venture between Lifera, a biopharmaceutical business owned by the Public Investment Fund, and Centogene, a German life science partner for data-driven answers in rare and neurodegenerative illnesses.

On the second day of the Global Healthspan Summit in Riyadh, Peter Bauer, the Chief Medical and Genomic Officer of Centogene, and Ibrahim Al-Juffali, the Chairman of Lifera, discussed a new age of comprehending illnesses, expediting precision medicine, and diagnosing patients.

Lifera and Centogene established a strategic partnership, throughout June of this year,  that will expand local and regional access to top-notch multiomic testing throughout the Kingdom and the Gulf area. By providing patients, health systems, biopharma businesses, and research institutes with state-of-the-art genomic and multiomic testing services, Lifera Omics aims to improve the lives of people in the Gulf area.

To provide a complete clinical picture, Lifera Omics integrates data from phenomics, genomes, transcriptomics, epigenomics, proteomics, and metabolomics. The partnership between Lifera and Centogene will foster both domestic and foreign talent while offering Saudi Arabians training possibilities. Saudis will have the chance to visit Germany as part of their training.

Lifera wants to build alliances with top domestic and foreign businesses and draw in targeted investments to expand local capabilities and support home production in the industry.

The production of vital and life-saving pharmaceutical goods, such as insulin, vaccines, monoclonal antibodies, plasma treatments, cell and gene therapies, and novel small compounds, is the goal of investment.